童颜针变强心针 江苏吴中业绩创近5年新高

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. has successfully turned around its financial performance, achieving significant revenue growth and profitability primarily driven by its aesthetic medicine business, particularly the launch of the AestheFill product [1][2]. Financial Performance - In 2024, the company reported a revenue of 1,598.51 million yuan and a gross profit of 772.58 million yuan, marking a year-on-year increase of 228.95 million yuan, or 42.12%. The net profit reached 70.48 million yuan, the highest in nearly five years [1][2]. - The first quarter of 2025 saw the aesthetic medicine segment generate revenue of 113.02 million yuan with a gross profit of 92.57 million yuan, while the pharmaceutical segment reported revenue of 197.53 million yuan, a decrease of 218.44 million yuan year-on-year [3]. Strategic Developments - Jiangsu Wuzhong has shifted its strategy towards a dual focus on pharmaceuticals and aesthetic medicine since 2020, establishing a wholly-owned subsidiary, Wuzhong Aesthetics, to enter the aesthetic market [2]. - The company introduced the AestheFill product, which received regulatory approval in January 2024 and has significantly contributed to revenue growth [2]. Market Position and Product Line - As of the end of 2024, the aesthetic medicine sales team expanded to 55 members, collaborating with 537 medical aesthetic institutions, including well-known brands like Meilai and Huahan [3]. - The product line has diversified to include various aesthetic injectables, such as AestheFill, recombinant collagen, and sodium hyaluronate-PDRN, achieving comprehensive coverage in the regenerative anti-aging injection market [3].